Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Shanthakumar Tyavanagimatt"'
Publikováno v:
Viruses, Vol 2, Iss 11, Pp 2409-2435 (2010)
ST-246 (Tecovirimat) is a small synthetic antiviral compound being developed to treat pathogenic orthopoxvirus infections of humans. The compound was discovered as part of a high throughput screen designed to identify inhibitors of vaccinia virus-ind
Externí odkaz:
https://doaj.org/article/8351d4bf79d846408483ab895a1ef70f
Autor:
Stephen T Oh, Ruben Mesa, Claire Harrison, Prithviraj Bose, Aaron T. Gerds, Mark L. Heaney, Vikas Gupta, Bart L. Scott, Jean-Jacques Kiladjian, Alessandro Lucchesi, Sarah Buckley, Shanthakumar Tyavanagimatt, Karisse Roman-Torres, John Mascarenhas, Srdan Verstovsek
Publikováno v:
Blood. 140:1518-1521
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45f2d3332762fbb8518617fcff1590d7
https://doi.org/10.1182/blood-2022-156936
https://doi.org/10.1182/blood-2022-156936
Autor:
Stephen Oh, Ruben Mesa, Claire Harrison, Prithviraj Bose, Aaron Gerds, Vikas Gupta, Ashwin Swami, Shanthakumar Tyavanagimatt, Sarah Buckley, Karisse Roman-Torres, Srdan Verstovsek
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S156
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ac1996a7693b0bbba66d9ab85cab193
https://doi.org/10.1016/s2152-2650(22)00954-5
https://doi.org/10.1016/s2152-2650(22)00954-5
Autor:
Stephen, Oh, Ruben, Mesa, Claire, Harrison, Prithviraj, Bose, Aaron, Gerds, Vikas, Gupta, Ashwin, Swami, Shanthakumar, Tyavanagimatt, Sarah, Buckley, Karisse, Roman-Torres, Srdan, Verstovsek
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S327
Pacritinib (PAC) is a novel JAK2/IRAK1 inhibitor approved for patients with myelofibrosis (MF) and platelets50×10This analysis included PERSIST-2 patients with platelet count ≤100×10The analysis included 106 patients on PAC 200mg BID, 104 on 400m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76e507a19ff34e51edde1c6f8eef2867
https://doi.org/10.1016/s2152-2650(22)01439-2
https://doi.org/10.1016/s2152-2650(22)01439-2
Autor:
Adam R. Craig, Valentín García-Gutiérrez, Carole B. Miller, Adam J. Mead, Alessandro M. Vannucchi, Stephen T. Oh, Diane R. Mould, Miklos Egyed, John Mascarenhas, Raajit K. Rampal, Michael R. Savona, Sri Devineni, Kaori Ito, Jean-Jacques Kiladjian, Aaron T. Gerds, Claire N. Harrison, Jeanne Palmer, Karisse Roman-Torres, Shanthakumar Tyavanagimatt, Moshe Talpaz, Jennifer O'Sullivan, Prithviraj Bose, Sarah A. Buckley, Bart L. Scott, Abdulraheem Yacoub, Jennifer A. Smith
Publikováno v:
Blood Adv
PAC203 is a randomized dose-finding study of pacritinib, an oral JAK2/IRAK1 inhibitor, in patients with advanced myelofibrosis who are intolerant of or resistant to ruxolitinib. Patients were randomized 1:1:1 to pacritinib 100 mg once per day, 100 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::197465cd8da7df3d035d8681e7a61938
https://europepmc.org/articles/PMC7686901/
https://europepmc.org/articles/PMC7686901/
Autor:
John Mascarenhas, Michael R. Savona, Moshe Talpaz, Adam J. Mead, Alessandro M. Vannucchi, Aaron T. Gerds, Bart L. Scott, Miklos Egyed, Diane R. Mould, Sarah A. Buckley, Jennifer A. Smith, Jennifer O'Sullivan, Shanthakumar Tyavanagimatt, Claire N. Harrison, Abdulraheem Yacoub
Publikováno v:
Blood. 134:667-667
Background: Pacritinib (PAC), an oral JAK2/IRAK 1 inhibitor, has demonstrated clinical benefit in myelofibrosis (MF) patients in two prior Phase 3 studies (PERSIST-1, PERSIST-2). PAC203 is a randomized Phase 2 dose-finding study in patients with MF w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a8fc62a471555ed0c25b5a7e1e0a024
https://doi.org/10.1182/blood-2019-129293
https://doi.org/10.1182/blood-2019-129293